A Phase I, Open-Label, Multicentre Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2811 in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs AZD 2811 (Primary) ; Irinotecan
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 08 Feb 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2019.
- 06 Jun 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.